Placebo News and Research

RSS

Regurin XL capsule for the treatment of OAB launched in UK

Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R) XL provides rapid, significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects(2-7).

7 Sep 2009

Alzheimer’s disease researcher joins UBC's European Scientific Advisory Board

United BioSource Corporation (UBC) announced this summer at ICAD 2009 that Bengt Winblad, MD, PhD has joined its European Scientific Advisory Board for CNS Clinical Trials. Professor Winblad is one of the world’s leading Alzheimer’s disease researchers and currently serves as Professor of Geriatric Medicine and Chief Physician at the Karolinska University Hospital, Huddinge, and the Karolinska Institute in Stockholm, Sweden.

5 Sep 2009

Dilafor Phase II clinical trial completes

Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth.

4 Sep 2009

Shire receives FDA approval for INTUNIV extended release tablets

Shire plc, the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.

4 Sep 2009

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company’s potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).

4 Sep 2009

No performance enhancing effect of quercetin seen, according to a study

The antioxidant quercetin is increasingly being marketed as a supplement that boosts athletic performance, but a new University of Georgia study finds that it is no better than a placebo.

4 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

New Marketing Authorization Application for Rhucin submitted to the EMEA by Pharming

Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has submitted the Marketing Authorization Application (MAA) for Rhucin for the treatment of acute attacks of Hereditary Angioedema (HAE) to the European Medicines Agency (EMEA).

3 Sep 2009

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Biogen Idec today announced more than 70 platform and poster presentations from the company’s multiple sclerosis (MS) franchise being presented during the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.

3 Sep 2009

CORD I phase III clinical trial results of XIAFLEX published

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that The New England Journal of Medicine (NEJM) has published in its September 3rd edition, the Company's pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) a novel, first-in-class, biologic for the nonsurgical treatment of Dupuytren's contracture.

3 Sep 2009

New method for treating hand disorder discovered

Researchers in the Department of Orthopaedics at Stony Brook University Medical Center have developed an injectable form of the enzyme, collagenase, that significantly improves outcomes of Dupuytren's contracture (or disease), a debilitating disorder caused by progressive accumulation of collagen that deforms fingers and limits motion. Reported in September 3, 2009, issue of The New England Journal of Medicine, the study involved treatment of 308 patients with Duputren's disease in 16 sites nationwide. The results indicate that the injections are safe and effective.

3 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009

FDA approves Astepro nasal spray 0.15% for the treatment of the symptoms of seasonal allergies

The U.S. Food and Drug Administration (FDA) has approved Astepro (azelastine) nasal spray 0.15% for the treatment of the symptoms of seasonal and perennial allergic rhinitis.

2 Sep 2009

Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon

A groundbreaking new treatment for obesity is to begin clinical trials in January. Madrona Ventures Inc., an American publicly listed company (OTCBB:MDRV), has acquired the treatment's European patent and the pending American patent application.

2 Sep 2009

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

Knopp Neurosciences Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of KNS-760704 in amyotrophic lateral sclerosis (ALS).

2 Sep 2009

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.

2 Sep 2009

PROTECT clinical study aimed at the assessment of rolofylline effects

Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.

2 Sep 2009

Positive results from second pivotal phase III trial for Lodotra

Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM).

2 Sep 2009

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

In a major international trial, researchers from McMaster University in Canada, found that the hypertension drug irbesartan reduced the risk of heart failure complications and the combination of stroke, other embolic events and transient ischemic events, also known as ministrokes, in patients with atrial fibrillation.

2 Sep 2009

Study reveals that baking soda benefits patients with advanced chronic kidney disease

A daily dose of sodium bicarbonate—baking soda, already used for baking, cleaning, acid indigestion, sunburn, and more—slows the decline of kidney function in some patients with advanced chronic kidney disease (CKD), reports an upcoming study in the Journal of the American Society of Nephrology (JASN).

2 Sep 2009

Placebo News and Research

Regurin XL capsule for the treatment of OAB launched in UK

Alzheimer’s disease researcher joins UBC's European Scientific Advisory Board

Dilafor Phase II clinical trial completes

Shire receives FDA approval for INTUNIV extended release tablets

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

No performance enhancing effect of quercetin seen, according to a study

Results of Phase 2 rheumatoid arthritis clinical trial announced

New Marketing Authorization Application for Rhucin submitted to the EMEA by Pharming

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

CORD I phase III clinical trial results of XIAFLEX published

New method for treating hand disorder discovered

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

FDA approves Astepro nasal spray 0.15% for the treatment of the symptoms of seasonal allergies

Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

PROTECT clinical study aimed at the assessment of rolofylline effects

Positive results from second pivotal phase III trial for Lodotra

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

Study reveals that baking soda benefits patients with advanced chronic kidney disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News